US009409991B2

(12) **United States Patent**
Thiry et al.

(10) **Patent No.: US 9,409,991 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **PHARMACEUTICAL COMPOSITIONS OF ANTIBODIES FOR TREATMENT OF DISEASES CAUSED BY INFLUENZA VIRUS**

(75) Inventors: **Michel Thiry**, Trooz (BE); **Andrey Martyushev-Poklad**, Moscow (RU)

(73) Assignee: **THERANOR SPRL** (BE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 340 days.

(21) Appl. No.: **13/001,498**

(22) PCT Filed: **Jun. 26, 2009**

(86) PCT No.: **PCT/BE2009/000035**

§ 371 (c)(1),
(2), (4) Date: **Mar. 4, 2011**

(87) PCT Pub. No.: **WO2009/155670**

PCT Pub. Date: **Dec. 30, 2009**

(65) **Prior Publication Data**

US 2011/0177081 A1 Jul. 21, 2011

(30) **Foreign Application Priority Data**

Jun. 27, 2008 (EP) 08447031

(51) **Int. Cl.**

C07K 16/28 (2006.01)
A61K 39/00 (2006.01)
A61K 39/395 (2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/2896*** (2013.01); ***C07K 16/28*** (2013.01); ***C07K 16/2866*** (2013.01); *A61K 39/3955* (2013.01); *A61K 2039/505* (2013.01); *C07K 2316/96* (2013.01); *C07K 2317/34* (2013.01)

(58) **Field of Classification Search**

CPC A61K 2039/505; C07K 16/28; C07K 16/2866; C07K 16/2896; C07K 2317/34; C07K 2316/96

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,287,853	B1 *	9/2001	Pestka et al.	435/320.1
2004/0208874	A1 *	10/2004	Khare	424/145.1
2005/0153910	A1	7/2005	Matsumoto et al.	
2006/0115475	A1	6/2006	Carton et al.	
2007/0098716	A1	5/2007	Duffy et al.	
2008/0317811	A1 *	12/2008	Andre et al.	424/423
2009/0068684	A1 *	3/2009	Moritz et al.	435/7.23

FOREIGN PATENT DOCUMENTS

EP	1 295 606		3/2003
WO	WO2006/054177	*	5/2006

OTHER PUBLICATIONS

Schroder, M. et al. TLR3 in antiviral immunity: key player or bystander. Trends in Immunology, 2005, vol. 26, No. 9, p. 462-468.*
Edelmann, K.H. et al. Does toll-like receptor 3 play a biological role in virus infection. Virology, 2004, vol. 322, p. 231-238.*
International Search Report dated Aug. 20, 2010 in PCT/BE2009/000035 filed Jun. 26, 2009 (WO2009/155670).
International Preliminary Report on Patentability issued Jan. 5, 2011 in PCT/BE2009/000035 filed Jun. 26, 2009 (WO2009/155670).
Kenji Funami, et al., "The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling", International Immunology vol. 16, No. 8, Advance Access publication Jun. 28, 2004, copyright 2004 The Japanese Society for Immunology, pp. 1143-1154, cited in the Annex to EPO Form 2004, communication pursuant to Rule 71(3) EPC in priority EPO Application 08 447 031.9 filed Jun. 27, 2008.
"Homeopathy", Wikipedia article http://en.wikipedia.org/wiki/Homeopathy, printed Jul. 28, 2010, 28 pages, cited in the Annex to EPO Form 2004, communication pursuant to Rule 71(3) EPC in priority EPO Application 08 447 031.9 filed Jun. 27, 2008.
Chen, Keqiang, et al., "Toll-like receptors in inflammation, infection and cancer", International Immunopharmacology, Elsevier, Amsterdam, NL, vol. 7, No. 10, Jul. 31, 2007, pp. 1271-1285, XP022182172 ISSN: 1567-5769, cited in International Search Report mailed Feb. 8, 2010 of PCT/BE2009/00035 filed Jun. 26, 2009 (WO2009/155670).
Matsumoto, Misako et al., "Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling", Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando, Florida, U.S., vol. 293, No. 5, May 24, 2002, pp. 1364-1369, XP002974969 ISSN: 0006-291X, cited in International Search Report mailed Feb. 8, 2010 of PCT/BE2009/00035 filed Jun. 26, 2009 (WO2009/155670).
Duffy, Karen E., et al., "Down modulation of human TLR3 function by a monoclonal antibody", Cellular Immunology, Academic Press, San Diego, CA, U.S., vol. 248, No. 2, Dec. 26, 2007, pp. 103-114, XP022401829 ISSN: 0008-8749, cited in International Search Report mailed Feb. 8, 2010 of PCT/BE2009/00035 filed Jun. 26, 2009 (WO2009/155670).
Turner, Stephen J., et al., "Disregulated Influenza A Virus-Specific CD8+ T Cell Homeostasis in the Absence of Ifn-gamma signaling", Journal of Immunology, Baltimore, MD, vol. 178, No. 12, Jun. 15, 2007, pp. 7616-7622, XP002506551 ISSN: 0022-1767, cited in International Search Report mailed Feb. 8, 2010 of PCT/BE2009/00035 filed Jun. 26, 2009 (WO2009/155670).
Wood, Peter, Understanding Immunology: Second Edition, Pearson Education Limited, Essex, England, 2006.
Shih, Heather H., Discovery Process for Antibody-Based Therapeutics, Development of Antibody-Based Therapeutics, Chapter 2, M.A. Tabrizi et al (eds), 2012, pp. 9-32.

(Continued)

Primary Examiner — Robert Landsman
Assistant Examiner — Bruce D Hissong
(74) *Attorney, Agent, or Firm* — Hovey Williams LLP

(57) **ABSTRACT**

A pharmaceutical composition for prevention or treatment of viral infections including a formulation of full antibodies or fragments of antibodies specific to at least one of the following peptide sequences of toll-like receptor type 3: FYWNVSVHRVLGFKE (Seq ID NO:1), EYAAYIIHAYKD (Seq ID NO: 2), or to peptide sequence of interferon gamma receptor beta chain: LIKYWFHTPPSIPLQIEEYL (Seq ID NO: 3), or to peptide sequence of interferon gamma receptor alpha chain: SIILPKSLISW (Seq ID NO: 4).

15 Claims, No Drawings